Timothy A Graubert

List of Publications by Year
in descending order

123	19,311	34076 52	25770 108
papers	citations	h-index	g-index

126	126	126	24738
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Recurring Mutations Found by Sequencing an Acute Myeloid Leukemia Genome. New England Journal of Medicine, 2009, 361, 1058-1066.	13.9	2,009
2	Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature, 2012, 481, 506-510.	13.7	1,795
3	DNMT3AMutations in Acute Myeloid Leukemia. New England Journal of Medicine, 2010, 363, 2424-2433.	13.9	1,777
4	The Origin and Evolution of Mutations in Acute Myeloid Leukemia. Cell, 2012, 150, 264-278.	13.5	1,365
5	DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. Nature, 2008, 456, 66-72.	13.7	1,275
6	Clonal Architecture of Secondary Acute Myeloid Leukemia. New England Journal of Medicine, 2012, 366, 1090-1098.	13.9	688
7	Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia. Nature, 2015, 518, 552-555.	13.7	685
8	TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes. New England Journal of Medicine, 2016, 375, 2023-2036.	13.9	663
9	Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes. Nature Genetics, 2012, 44, 53-57.	9.4	513
10	Sca-1pos Cells in the Mouse Mammary Gland Represent an Enriched Progenitor Cell Population. Developmental Biology, 2002, 245, 42-56.	0.9	491
11	SciClone: Inferring Clonal Architecture and Tracking the Spatial and Temporal Patterns of Tumor Evolution. PLoS Computational Biology, 2014, 10, e1003665.	1.5	400
12	How do cytotoxic lymphocytes kill their targets?. Current Opinion in Immunology, 1998, 10, 581-587.	2.4	353
13	Functional Heterogeneity of Genetically Defined Subclones in Acute Myeloid Leukemia. Cancer Cell, 2014, 25, 379-392.	7.7	330
14	Immune Escape of Relapsed AML Cells after Allogeneic Transplantation. New England Journal of Medicine, 2018, 379, 2330-2341.	13.9	322
15	Association Between Mutation Clearance After Induction Therapy and Outcomes in Acute Myeloid Leukemia. JAMA - Journal of the American Medical Association, 2015, 314, 811.	3.8	302
16	Mutant U2AF1 Expression Alters Hematopoiesis and Pre-mRNA Splicing InÂVivo. Cancer Cell, 2015, 27, 631-643.	7.7	259
17	Integrated analysis of germline and somatic variants in ovarian cancer. Nature Communications, 2014, 5, 3156.	5.8	253
18	Patterns and functional implications of rare germline variants across 12 cancer types. Nature Communications, 2015, 6, 10086.	5.8	243

#	Article	IF	Citations
19	Use of Whole-Genome Sequencing to Diagnose a Cryptic Fusion Oncogene. JAMA - Journal of the American Medical Association, 2011, 305, 1577.	3.8	233
20	Acquired copy number alterations in adult acute myeloid leukemia genomes. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 12950-12955.	3.3	231
21	The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. Cancer Cell, 2016, 29, 574-586.	7.7	227
22	Genomic analysis of germ line and somatic variants in familial myelodysplasia/acute myeloid leukemia. Blood, 2015, 126, 2484-2490.	0.6	207
23	Functions of Replication Protein A as a Sensor of R Loops and a Regulator of RNaseH1. Molecular Cell, 2017, 65, 832-847.e4.	4.5	205
24	Somatic mutations and germline sequence variants in the expressed tyrosine kinase genes of patients with de novo acute myeloid leukemia. Blood, 2008, 111, 4797-4808.	0.6	198
25	A High-Resolution Map of Segmental DNA Copy Number Variation in the Mouse Genome. PLoS Genetics, 2007, 3, e3.	1.5	196
26	TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups. Leukemia, 2019, 33, 1747-1758.	3.3	195
27	SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS. Blood, 2020, 136, 157-170.	0.6	195
28	Recruitment of Bone Marrow-Derived Endothelial Cells to Sites of Pancreatic Â-Cell Injury. Diabetes, 2004, 53, 91-98.	0.3	172
29	Quality of life and mood of patients and family caregivers during hospitalization for hematopoietic stem cell transplantation. Cancer, 2015, 121, 951-959.	2.0	157
30	Cellular stressors contribute to the expansion of hematopoietic clones of varying leukemic potential. Nature Communications, 2018, 9, 455.	5.8	150
31	Identification of a Novel <emph type="ital">TP53</emph> Cancer Susceptibility Mutation Through Whole-Genome Sequencing of a Patient With Therapy-Related AML. JAMA - Journal of the American Medical Association, 2011, 305, 1568.	3.8	146
32	Granzyme A Initiates an Alternative Pathway for Granule-Mediated Apoptosis. Immunity, 1999, 10, 595-605.	6.6	140
33	Functional analysis of a chromosomal deletion associated with myelodysplastic syndromes using isogenic human induced pluripotent stem cells. Nature Biotechnology, 2015, 33, 646-655.	9.4	130
34	Imputation of Exome Sequence Variants into Population- Based Samples and Blood-Cell-Trait-Associated Loci in African Americans: NHLBI GO Exome Sequencing Project. American Journal of Human Genetics, 2012, 91, 794-808.	2.6	123
35	Spliceosome Mutations Induce R Loop-Associated Sensitivity to ATR Inhibition in Myelodysplastic Syndromes. Cancer Research, 2018, 78, 5363-5374.	0.4	117
36	Clonal Architecture of Secondary Acute Myeloid Leukemia Defined by Single-Cell Sequencing. PLoS Genetics, 2014, 10, e1004462.	1.5	115

#	Article	IF	Citations
37	Health care utilization and endâ€ofâ€life care for older patients with acute myeloid leukemia. Cancer, 2015, 121, 2840-2848.	2.0	113
38	The impact of copy number variation on local gene expression in mouse hematopoietic stem and progenitor cells. Nature Genetics, 2009, 41, 430-437.	9.4	112
39	Roles of Sca-1 in hematopoietic stem/progenitor cell function. Experimental Hematology, 2005, 33, 836-843.	0.2	108
40	Mutant U2AF1-expressing cells are sensitive to pharmacological modulation of the spliceosome. Nature Communications, 2017, 8, 14060.	5.8	99
41	Splicing factor gene mutations in hematologic malignancies. Blood, 2017, 129, 1260-1269.	0.6	99
42	Sca-1 negatively regulates proliferation and differentiation of muscle cells. Developmental Biology, 2005, 283, 240-252.	0.9	96
43	Rapid expansion of preexisting nonleukemic hematopoietic clones frequently follows induction therapy for de novo AML. Blood, 2016, 127, 893-897.	0.6	94
44	Genome-wide association study to identify novel loci associated with therapy-related myeloid leukemia susceptibility. Blood, 2009, 113, 5575-5582.	0.6	93
45	Mutation Clearance after Transplantation for Myelodysplastic Syndrome. New England Journal of Medicine, 2018, 379, 1028-1041.	13.9	93
46	Sequencing a mouse acute promyelocytic leukemia genome reveals genetic events relevant for disease progression. Journal of Clinical Investigation, 2011, 121, 1445-1455.	3.9	91
47	Distinct patterns of mutations occurring in de novo AML versus AML arising in the setting of severe congenital neutropenia. Blood, 2007, 110, 1648-1655.	0.6	88
48	Identification of somatic JAK1 mutations in patients with acute myeloid leukemia. Blood, 2008, 111, 4809-4812.	0.6	84
49	Stem cell expression of the AML1/ETO fusion protein induces a myeloproliferative disorder in mice. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 15184-15189.	3.3	81
50	Clonal hematopoiesis and measurable residual disease assessment in acute myeloid leukemia. Blood, 2020, 135, 1729-1738.	0.6	80
51	Pathogenic Variants for Mendelian and Complex Traits in Exomes of 6,517 European and African Americans: Implications for the Return of Incidental Results. American Journal of Human Genetics, 2014, 95, 183-193.	2.6	78
52	High NPM1-mutant allele burden at diagnosis predicts unfavorable outcomes in de novo AML. Blood, 2018, 131, 2816-2825.	0.6	64
53	A pilot study of high-throughput, sequence-based mutational profiling of primary human acute myeloid leukemia cell genomes. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 14275-14280.	3.3	55
54	Genetics of Myelodysplastic Syndromes: New Insights. Hematology American Society of Hematology Education Program, 2011, 2011, 543-549.	0.9	49

#	Article	IF	Citations
55	Discovery and Pharmacological Characterization of JNJ-64619178, a Novel Small-Molecule Inhibitor of PRMT5 with Potent Antitumor Activity. Molecular Cancer Therapeutics, 2021, 20, 2317-2328.	1.9	48
56	Subclones dominate at MDS progression following allogeneic hematopoietic cell transplant. JCI Insight, 2018, 3, .	2.3	48
57	Integrated Genomic Analysis Implicates Haploinsufficiency of Multiple Chromosome 5q31.2 Genes in De Novo Myelodysplastic Syndromes Pathogenesis. PLoS ONE, 2009, 4, e4583.	1.1	48
58	Enhanced green fluorescent protein targeted to the Sca-1 (Ly-6A) locus in transgenic mice results in efficient marking of hematopoietic stem cells in vivo. Experimental Hematology, 2003, 31, 159-167.	0.2	47
59	Identification of Candidate Alkylator-Induced Cancer Susceptibility Genes by Whole Genome Scanning in Mice. Cancer Research, 2006, 66, 5029-5038.	0.4	44
60	Comprehensive genomic analysis reveals FLT3 activation and a therapeutic strategy for a patient with relapsed adult B-lymphoblastic leukemia. Experimental Hematology, 2016, 44, 603-613.	0.2	44
61	Therapy related acute myeloid leukemia in breast cancer survivors, a population-based study. Breast Cancer Research and Treatment, 2009, 118, 593-598.	1.1	41
62	Phase I study of the aurora A kinase inhibitor alisertib with induction chemotherapy in patients with acute myeloid leukemia. Haematologica, 2017, 102, 719-727.	1.7	33
63	Detection of Dual IDH1 and IDH2 Mutations by Targeted Next-Generation Sequencing in Acute Myeloid Leukemia and Myelodysplastic Syndromes. Journal of Molecular Diagnostics, 2015, 17, 661-668.	1.2	31
64	Long-term outcomes of allogeneic stem cell transplant recipients after calcineurin inhibitor-induced neurotoxicity. British Journal of Haematology, 2003, 123, 110-113.	1.2	28
65	A mouse-based strategy for cyclophosphamide pharmacogenomic discovery. Journal of Applied Physiology, 2003, 95, 1352-1360.	1.2	27
66	Next-generation sequencing of cancer genomes: back to the future. Personalized Medicine, 2009, 6, 653-662.	0.8	26
67	wuHMM: a robust algorithm to detect DNA copy number variation using long oligonucleotide microarray data. Nucleic Acids Research, 2008, 36, e41.	6.5	25
68	A Randomized Double-Blind Trial of Hydroxychloroquine for the Prevention of Chronic Graft-versus-Host Disease after Allogeneic Peripheral Blood Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2007, 13, 1201-1206.	2.0	24
69	A synthetic small molecule stalls pre-mRNA splicing by promoting an early-stage U2AF2-RNA complex. Cell Chemical Biology, 2021, 28, 1145-1157.e6.	2.5	24
70	Isocitrate dehydrogenase 1 and 2 mutations, 2â€hydroxyglutarate levels, and response to standard chemotherapy for patients with newly diagnosed acute myeloid leukemia. Cancer, 2019, 125, 541-549.	2.0	23
71	Genomics of Acute Myeloid Leukemia. Cancer Journal (Sudbury, Mass), 2011, 17, 487-491.	1.0	20
72	Caspase-9 is required for normal hematopoietic development and protection from alkylator-induced DNA damage in mice. Blood, 2014, 124, 3887-3895.	0.6	20

#	Article	IF	Citations
73	Characterization of Ly-6M, a novel member of the Ly-6 family of hematopoietic proteins. Blood, 2000, 95, 3125-3132.	0.6	19
74	Alisertib plus induction chemotherapy in previously untreated patients with high-risk, acute myeloid leukaemia: a single-arm, phase 2 trial. Lancet Haematology,the, 2020, 7, e122-e133.	2.2	19
75	Recombinant retroviral systems for the analysis of drug resistant HIV. Nucleic Acids Research, 1993, 21, 4836-4842.	6.5	17
76	A Mouse Model of Alkylator-Induced Myelodysplastic Syndrome.. Blood, 2005, 106, 368-368.	0.6	17
77	Murine Models of Human Acute Myeloid Leukemia. Cancer Treatment and Research, 2009, 145, 183-196.	0.2	16
78	A phase 1 study of the antibodyâ€drug conjugate brentuximab vedotin with reâ€induction chemotherapy in patients with CD30â€expressing relapsed/refractory acute myeloid leukemia. Cancer, 2020, 126, 1264-1273.	2.0	15
79	Genomics in childhood acute myeloid leukemia comes of age. Nature Medicine, 2018, 24, 7-9.	15.2	14
80	Quantitative trait loci associated with susceptibility to therapy-related acute murine promyelocytic leukemia in hCG-PML/RARA transgenic mice. Blood, 2008, 112, 1434-1442.	0.6	11
81	Therapy-Related Myelodysplastic Syndrome: Models and Genetics. Biology of Blood and Marrow Transplantation, 2010, 16, S45-S47.	2.0	11
82	A Call to Action for Acute Lymphoblastic Leukemia. New England Journal of Medicine, 2014, 371, 1064-1066.	13.9	11
83	Pharmacogenetics of alkylator-associated acute myeloid leukemia. Pharmacogenomics, 2006, 7, 719-729.	0.6	10
84	New Molecular Abnormalities and Clonal Architecture in AML: From Reciprocal Translocations to Whole-Genome Sequencing. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2014, , e334-e340.	1.8	10
85	U2af1 is a haplo-essential gene required for hematopoietic cancer cell survival in mice. Journal of Clinical Investigation, 2021, 131, .	3.9	9
86	Phase II Clinical Trial of Alisertib, an Aurora a Kinase Inhibitor, in Combination with Induction Chemotherapy in High-Risk, Untreated Patients with Acute Myeloid Leukemia. Blood, 2018, 132, 766-766.	0.6	9
87	Targeting R-loop-associated ATR response in myelodysplastic syndrome. Oncotarget, 2019, 10, 2581-2582.	0.8	9
88	Mutations In the DNA Methyltransferase Gene DNMT3A Are Highly Recurrent In Patients with Intermediate Risk Acute Myeloid Leukemia, and Predict Poor Outcomes. Blood, 2010, 116, 99-99.	0.6	9
89	AML Genomics for the Clinician. Seminars in Hematology, 2014, 51, 322-329.	1.8	6
90	POU4F1 Is Associated with t(8;21) AML and Contributes Directly to Its Unique Transcriptional Signature.. Blood, 2009, 114, 2623-2623.	0.6	6

#	Article	IF	Citations
91	Integrated genomics of susceptibility to alkylator-induced leukemia in mice. BMC Genomics, 2010, 11, 638.	1.2	5
92	Identification of Polymorphisms Associated with Susceptibility to Therapy-Related MDS and AML.. Blood, 2007, 110, 15-15.	0.6	5
93	BRCA1 and BRCA2 Nucleotide Variants in Young Women with Therapy Related Acute Myeloid Leukemia.. Blood, 2009, 114, 1102-1102.	0.6	5
94	Dominant Negative Effects of the AML1/ETO Fusion Oncoprotein. Cell Cycle, 2005, 4, 33-36.	1.3	4
95	Redirecting T-Cells Against AML in a Multidimensional Targeting Space Using T-Cell Engaging Antibody Circuits (TEAC). Blood, 2019, 134, 2653-2653.	0.6	4
96	Prognostic understanding, quality of life (QOL), and mood in patients undergoing hematopoietic stem cell transplantation (HCT).. Journal of Clinical Oncology, 2014, 32, 219-219.	0.8	4
97	Spliceosome Mutant Myeloid Malignancies Are Preferentially Sensitive to PARP Inhibition. Blood, 2021, 138, 322-322.	0.6	4
98	Inhibition of ATR with AZD6738 (Ceralasertib) for the Treatment of Progressive or Relapsed Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: Safety and Preliminary Activity from a Phase Ib/II Study. Blood, 2021, 138, 1521-1521.	0.6	4
99	Case 37-2016. New England Journal of Medicine, 2016, 375, 2273-2282.	13.9	3
100	Combined Targeted Therapy for BRAF-Mutant, Treatment-Related Acute Myeloid Leukemia. JCO Precision Oncology, 2017, 1, 1-7.	1.5	3
101	Long: molecular tracking of CML with bilineal inv(16) myeloid and del(9) lymphoid blast crisis and durable response to CD19-directed CAR-T therapy. Leukemia, 2020, 34, 3050-3054.	3.3	3
102	Phase II Trial of the Tyrosine Kinase Inhibitor PKC412 in Advanced Systemic Mastocytosis: Preliminary Results.. Blood, 2006, 108, 3609-3609.	0.6	2
103	AML Genomics: Introduction. Seminars in Hematology, 2014, 51, 249.	1.8	1
104	Pathobiology of Acute Myeloid Leukemia. , 2018, , 913-923.		1
105	Comprehensive Genomic Copy Number and Sequence Analysis of 28 Chromosome 5q31.2 Candidate Genes in De Novo MDS.. Blood, 2007, 110, 117-117.	0.6	1
106	Complete Sequencing and Comparison of 12 Normal Karyotype M1 AML Genomes with 12 t(15;17) Positive M3-APL Genomes. Blood, 2011, 118, 404-404.	0.6	1
107	A Phase II Study of Intravenous Azacitidine Alone in Patients with Myelodysplastic Syndromes NCT00384956.. Blood, 2007, 110, 1451-1451.	0.6	1
108	ATR/CHK1/WEE1 Dependency in SRSF2-Mutated MDS/AML. Blood, 2021, 138, 3661-3661.	0.6	1

#	Article	IF	Citations
109	Phase I Study of Ixazomib Added to Chemotherapy in the Treatment of Acute Lymphoblastic Leukemia in Older Adults. Blood, 2020, 136, 41-42.	0.6	1
110	AML1 and Evi1: coconspirators in MDS/AML?. Blood, 2008, 111, 3916-3917.	0.6	0
111	A high resolution map of segmental DNA copy number variation in the mouse genome. PLoS Genetics, 2005, preprint, e3.	1.5	0
112	A Randomized, Double Blind Trial, of Hydroxychloroquine for the Prevention of Graft-Versus-Host Disease after Allogeneic Peripheral Blood Stem Cell Transplantation.. Blood, 2005, 106, 1800-1800.	0.6	0
113	Bcl2, a Candidate Murine Therapy-Related Acute Myeloid Leukemia Susceptibility Factor, Exhibits Strain-Dependent and Alkylator-Responsive Expression.. Blood, 2008, 112, 1499-1499.	0.6	0
114	Molecular basis of hematology. , 2010, , 1-26.		0
115	DNA Sequence of the Cancer Genome of a Patient with Therapy-Related Acute Myeloid Leukemia. Blood, 2010, 116, 580-580.	0.6	0
116	Recurrent DNMT3A Mutations In Patients with Myelodysplastic Syndrome. Blood, 2010, 116, 608-608.	0.6	0
117	Detection of Novel Mutations In MDS/AML by Whole Genome Sequencing. Blood, 2010, 116, 299-299.	0.6	0
118	Mutant U2AF1(S34F) Expression Alters Hematopoiesis in Mice. Blood, 2012, 120, 553-553.	0.6	0
119	Allele-Specific Effects Of U2AF1 Mutations On Alternative Splicing. Blood, 2013, 122, 2748-2748.	0.6	0
120	Prevalence and complications associated with off-label use of lenalidomide in older patients with myelodysplastic syndromes (MDS).. Journal of Clinical Oncology, 2017, 35, 7054-7054.	0.8	0
121	Clinical Outcomes Following Frontline Chemotherapy for Patients with Myeloid Malignancies Harboring Splicing Factor Mutations. Blood, 2018, 132, 4364-4364.	0.6	0
122	Single-Cell RNA-Seq Reveals AML Cellular Hierarchies Relevant to Clinical Outcomes and Immunity. Blood, 2018, 132, 542-542.	0.6	0
123	Potential Barriers to Clinical Trials of New Therapeutics for Myelodysplastic Syndromes: Wide Variation in Risk Definitions and Trial Enrollment Criteria. Blood, 2018, 132, 4378-4378.	0.6	0